2016 Apr 13. pii: g3.116.026997. doi: 10.1534/g3.116.026997. [Epub ahead of print]
Reis-Rodrigues P1, Kaul TK1, Ho JH1, Lucanic M2, Burkewitz K3, Mair WB3, Held JM4, Bohn LM1, Gill MS5.
Abstract
Under adverse environmental conditions the nematode C. elegans can enter an alternate developmental stage called the dauer larva. To identify lipophilic signaling molecules that influence this process, we screened a library of bioactive lipids and found that AM251, an antagonist of the human cannabinoid (CB) receptor, suppresses dauer entry in daf-2 insulin receptor mutants. AM251 acted synergistically with glucose supplementation indicating that the metabolic status of the animal influenced the activity of this compound. Similarly, loss of function mutations in the energy-sensing AMP-activated kinase subunit, aak-2, enhanced the dauer suppressing effects of AM251, while constitutive activation of aak-2 in neurons was sufficient to inhibit AM251 activity. Chemical epistasis experiments indicated that AM251 acts via G-protein signaling and requires the TGF-β ligand DAF-7, the insulin peptides DAF-28 and INS-6 and a functional ASI neuron to promote reproductive growth. AM251 also required the presence of the SER-5 serotonin receptor, but in vitro experiments suggest that this may not be via a direct interaction. Interestingly, we found that other antagonists of mammalian CB receptors also suppress dauer entry, while the non-selective CB receptor agonist, O-2545, not only inhibited the activity of AM251, but also was able to promote dauer entry when administered alone. Since worms do not have obvious orthologs of CB receptors, the effects of synthetic cannabinoids on neuroendocrine signaling in C. elegans are likely to be mediated via another, as yet unknown, receptor mechanism. However, we cannot exclude the existence of a non-canonical CB receptor in C. elegans.
Copyright © 2016 Author et al.
KEYWORDS:
C. elegans; dauer; synthetic cannabinoids
- PMID:
- 27172180
- [PubMed – as supplied by publisher]